ad image

Antibody

1 / 1
Timberlyne Therapeutics
Antibody

Timberlyne Therapeutics Secures $180M Series A to Advance CM313, a Promising Anti-CD38 Antibody for High-Need Diseases.

Timberlyne Therapeutics

PR-01-25-NI-07Jan 10, 2025
Mediar Therapeutics
Agreement

Mediar Therapeutics and Lilly Sign Global Licensing Agreement to Advance WISP1 Antibody to Treat Idiopathic Pulmonary Fibrosis

Mediar Therapeutics

PR-01-25-NI-06Jan 10, 2025
Spyre Therapeutics, Inc.
Antibody

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies

Spyre Therapeutics, Inc.

PR-12-24-NI-125Dec 03, 2024
EQT
Financing

EQT Life Sciences leads €54 Million Series A Financing of ATB Therapeutics

EQT

PR-11-24-NI-116Nov 20, 2024
Chime Biologics
ADC

Chime Biologics and Waterstone Jointly Develop and Manufacture Antibody-Drug Conjugate (ADC)

Chime Biologics

PR-10-24-NI-91Nov 12, 2024
World ADC
Announcement

Celebrating More than a Decade of Excellence at the World ADC Awards – Winners Announcement

World ADC

PR-10-24-NI-77Nov 08, 2024
1 / 1